RUNX1 and acute myeloid leukemia: In the context of the presence of the drug Enasidenib, we performed RUNX1: DNA-docking interactions employing the AML-associated RUNX1 mutants R142K, D171N, R174Q, P176H, R177Q in comparison to wild type (WT) RUNX1.